Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?

Lung cancer represents the major cause of cancer-related mortality in countries with a high degree of socioeconomic development, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all primary lung cancers (1,2).